Loading clinical trials...
Loading clinical trials...
China Faricimab Real World Evidence: Evaluation of Faricimab Effectiveness, Safety and Treatment Pattern, in Diabetic Macular Edema, Retinal Vein Occlusion and Neovascular Age-Related Macular Degeneration: The Farseeing Study
Conditions
Interventions
Faricimab
Locations
41
China
Joint Shantou International Eye Center
Shantou, Guangdong, China
The First Affiliated Hospital of Henan UN of Science and Technology
Luoyang, Henan, China
Taihe Hospital of Shiyan
Shiyan, Hubei, China
Xuzhou No.1 Peoples Hospital
Xuzhou, Jiangsu, China
Fushun Eye Hospital
Fushun, Liaoning, China
Panjin Central Hospital
Panjin, Liaoning, China
Start Date
May 9, 2024
Primary Completion Date
November 15, 2026
Completion Date
November 15, 2027
Last Updated
February 12, 2026
NCT07425522
NCT07308639
NCT07449936
NCT07449923
NCT07133438
NCT07228559
Reference Study ID Number: ML45401 https://forpatients.roche.com/
CONTACT
888-662-6728 (U.S. Only)global-roche-genentech-trials@gene.comLead Sponsor
Hoffmann-La Roche
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions